Prescription Scrutiny Is Pushing ADHD Telehealth Toward Coaching and Therapy

Last updated: July 10, 2026

Parents of kids who struggle with attention know the medication question well: when to raise it, whether to pursue it, and what comes after. A federal enforcement wave is now reshaping that question at the industry level—and what is replacing the old model looks more like what the science always recommended.

Major telehealth ADHD providers are pivoting toward therapy, coaching, and AI-supported care following federal prosecution and conviction of competitors for inappropriate stimulant distribution, Behavioral Health Business reported July 9. The shift is driven by regulatory pressure and by market reality: the prescription-first model is no longer sustainable, legally or clinically.

The surprise for parents is not the crackdown. It is that the industry is finally being pushed toward what decades of evidence backed all along.

TL;DR

Agave Health and Shimmer are adding therapy, behavioral coaching, and AI-supported care pathways to their ADHD offerings following federal scrutiny of telehealth prescribing practices.

Cerebral paid the U.S. government $3.6 million in a 2024 non-prosecution agreement; Done Global’s CEO and physician were convicted in November 2025 for inappropriate stimulant distribution.

An FDA-commissioned rapid review (Journal of Clinical Psychopharmacology, June 2026) found ADHD stimulant misuse among adults under 30 dropped from 7.5% (2016) to 3.7% (2023), partly linked to the 2022 Adderall shortage.

CBT, organizational skills training, and twice-weekly moderate exercise are evidence-backed first-line supports for executive function in ADHD—not alternatives to medication, but complements the prescription model rarely delivered.

DEA and HHS extended telehealth prescribing flexibilities through December 2026; a permanent framework with tighter controlled-substance prescribing requirements is under development.

Federal enforcement is reshaping the telehealth ADHD industry. Here is what parents need to know about what is changing, what the evidence says, and what to ask next.

Common questions

Should I stop my child’s ADHD medication because of these changes?

The regulatory changes are about provider practices, not the safety or effectiveness of ADHD medication for children who benefit from it. If your child’s medication is helping, the enforcement wave does not change that. What it signals is that medication alone was never a complete plan. The useful question is whether your child’s treatment also includes skill-building support for executive function, organization, and attention.

What does ADHD coaching actually do for a child?

ADHD coaching focuses on building the executive function skills—planning, organizing, prioritizing, self-monitoring—that attention challenges undercut. Unlike medication, which manages symptoms in the moment, behavioral coaching aims to build skills that transfer across settings and persist when the medication is not present. Evidence is strong for organizational skills training and CBT-based approaches in children with ADHD.

What questions should I ask my child’s ADHD provider?

Ask what behavioral support is included alongside any medication. Ask which executive function skills your child is being taught. Ask what happens if the current approach plateaus. And ask who is tracking whether your child is building skills, not just managing symptoms. A provider with no clear answer to those questions is delivering an incomplete model.

My child shows attention difficulties. How do I know where to start?

A screener is a useful starting point for understanding where your child’s attention, working memory, and processing challenges are concentrated. A screener is not a diagnosis, and it is not a substitute for a professional evaluation. If your child might need formal accommodations (an IEP or 504 plan), or you suspect a medical, vision, or hearing cause, pursue a professional evaluation—that is the only route to those supports. A screener fills the gap between “I know something is hard” and “I know what to work on.”

Telehealth ADHD clinics are pivoting to coaching and therapy now that the prescription-first model ran into federal prosecution. The evidence for skill-based ADHD care was there for decades. The enforcement wave is making it the business model. Tweet Now Follow Learning Success

What Is Changing, and Why Now

Agave Health and Shimmer are among the telehealth ADHD platforms adding behavioral coaching, therapy, and AI-supported care pathways alongside or in place of their previous medication-management focus. The shift follows a sustained period of federal enforcement that has restructured incentives across the telehealth ADHD space.

In 2024, Cerebral agreed to pay the U.S. government $3.6 million in a non-prosecution agreement over its prescribing practices. In November 2025, Done Global’s CEO and top physician were convicted for inappropriate stimulant distribution and face up to 20 years in prison. The DEA and HHS have extended telemedicine prescribing flexibilities through December 2026 for a fourth time, but the permanent regulatory framework under development would impose stricter requirements on providers who prescribe controlled substances via telehealth without a prior in-person visit.

A parallel data point sharpens the picture. An FDA-commissioned rapid review published in the Journal of Clinical Psychopharmacology in June 2026 found that ADHD stimulant misuse among adults under 30 fell from 7.5 percent in 2016 to 3.7 percent in 2023—a decline researchers partly attribute to the 2022 nationwide Adderall shortage. That 50 percent drop is not a story about behavioral change. It is a story about supply. When prescriptions became harder to obtain, misuse fell by half.

What the coverage gets wrong

Most reporting on the ADHD telehealth crackdown frames it as a corporate misconduct story with regulatory enforcement as the resolution. What it underreports is the clinical dimension: evidence-based ADHD treatment guidelines have included behavioral intervention alongside medication for decades. CBT, organizational skills training, and regular exercise are first-line recommendations—not alternatives. A telehealth model that started and ended with a prescription was always delivering an incomplete answer, and the enforcement wave is forcing providers to build the rest of it. For parents, the more useful read on this story is not “bad actors got caught” but “the care model is finally catching up to what the evidence required.”

The Evidence Was Never Hard to Find

Coverage of the telehealth ADHD crackdown frames it as a story about abuse prevention and corporate cleanup. That framing is accurate as far as it goes. What it misses is the clinical question sitting inside the enforcement story: the prescription-first model was never what the evidence actually called for.

Evidence-based ADHD treatment guidelines have recommended behavioral intervention alongside medication for decades. CBT has the strongest evidence base among non-medication approaches. Organizational skills training and daily report cards consistently produce the strongest real-world executive function improvements in structured reviews. Multiple meta-analyses confirm that exercise at moderate intensity at least twice weekly over 12-week periods measurably improves working memory, inhibition, and cognitive flexibility in children with ADHD. These are not fringe alternatives. They are first-line recommendations that a 15-minute intake and an auto-refill platform had no structural room to deliver.

The gap matters because ADHD is not one thing. Attention, working memory, executive function, and processing speed are distinct cognitive systems, and a prescription that smooths dopamine signaling does not build the executive function pathways that practice builds. Special education’s own research documents what happens when a support is handed out because it is easier than addressing the actual gap: the incentive to build the underlying skill disappears, and dependence sets in. A telehealth model that starts and ends with a prescription was always delivering half the answer.

Key Takeaways:

Telehealth ADHD providers are adding coaching and therapy under regulatory pressure: Agave Health and Shimmer are expanding beyond medication management following federal conviction of competitors for inappropriate stimulant distribution and a restructuring of telehealth prescribing rules.

ADHD stimulant misuse fell 50 percent in seven years, partly due to supply: An FDA-commissioned review (Journal of Clinical Psychopharmacology, June 2026) found misuse among adults under 30 dropped from 7.5% in 2016 to 3.7% in 2023, linked in part to the 2022 Adderall shortage.

Evidence for non-medication ADHD approaches is first-line, not alternative: CBT, organizational skills training, and twice-weekly exercise each show strong evidence for improving executive function in children with ADHD—recommendations that were always in the guidelines, and rarely in the telehealth model.

What to Ask About Your Child’s ADHD Care

The industry shift is a market signal, not a verdict on any individual child’s treatment. Medication helps some children create the window of calm attention that makes skill-building possible. The question is whether the skill-building is actually happening inside that window.

If your child receives ADHD care primarily or exclusively through a telehealth provider, now is a useful time to ask what comes alongside any prescription. What behavioral support is built into the plan? Who is teaching your child to organize, plan, prioritize, and self-monitor? What is the provider’s answer if the current approach plateaus? A provider with no clear response to those questions is delivering an incomplete model—regardless of whether their prescribing practices are legal.

The enforcement wave is forcing ADHD telehealth to build what it should have included from the start. For parents, the useful move is to evaluate the full picture of what your child is currently getting and what skills they are actively building—not to panic about the enforcement, but to let it prompt the right questions.

Your child’s ability to strengthen focus, plan, and build executive function is real—and it grows with targeted practice. The obstacle was never a lack of evidence for that. It was a care model that treated the prescription as the destination and had no room left over for the skill-building the evidence demanded. That model is cracking. What replaces it is closer to what actually moves outcomes.

If you want a clear picture of which processing systems are making attention and learning harder for your child—and a roadmap built around building those skills, not just labeling the gap—start with a free AI assessment at Learning Success All Access.